BAIYUNSHAN PH: Ke Gan Li Yan Oral Solution enters Phase III clinical trials
BAIYUNSHAN PH announced that its subsidiary Wanglaoji Pharmaceutical has initiated the Phase III clinical trial of Ke Gan Li Yan oral solution. This drug received its new drug certificate in 1997 and is primarily used for the treatment of acute pharyngitis, with the effects of dispelling wind and clearing heat, detoxifying, and benefiting the throat. Wanglaoji Pharmaceutical obtained clinical trial approval from the National Medical Products Administration in February 2024 and has now officially commenced the relevant trials
According to the Zhitong Finance APP, Baiyunshan (00874) announced that its subsidiary Guangzhou Wanglaoji Pharmaceutical Co., Ltd. ("Wanglaoji Pharmaceutical") recently held a kickoff meeting for the Phase III clinical trial of Keguanli Throat Oral Solution for the treatment of acute pharyngitis (exterior wind-heat syndrome), and this Phase III clinical trial project has officially commenced.
Keguanli Throat Oral Solution obtained its new drug certificate and production approval in 1997 and is an exclusive product of Wanglaoji Pharmaceutical. It is included in the 2025 edition of the Pharmacopoeia of the People's Republic of China, with functions of dispelling wind and clearing heat, detoxifying, and benefiting the throat, mainly used for colds caused by exterior wind-heat invasion and internal disturbance by pathogenic heat. Wanglaoji Pharmaceutical received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration in February 2024, agreeing to conduct confirmatory clinical trials for acute pharyngitis (exterior wind-heat syndrome) (i.e., Phase III clinical trials). Wanglaoji Pharmaceutical has recently officially launched the Phase III clinical trial
